XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.06

+0.3%

Dec 26 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Cacaito who wrote (8469)	1/25/1999 10:26:00 AM
From: aknahow	Read Replies (1) of 17367

Just a reminder of the importance of what you have told us. In 1996 Centoxin was turned down for approval in the U.K. Here is cut and paste on this drug. Source is Giroir, in Lancet correspondence. "In another trial in 269 patients with meningococcal sepsis HA-1A reduced mortality by 30% (p<0·08).5" Think this demonstrates why XOMA would continue the trial to assure it has a better chance to gain approval, since p<0.08 with a 305 reduction in mortality was not considered sufficient in the past.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next